Targeted Radionuclide Therapy (TRT) is an innovative approach to cancer treatment that combines the precision of targeted therapies with the cytotoxic power of radiation. TRT employs radiopharmaceuticals, molecules that selectively bind to tumour cells and deliver radiation directly to the tumour, minimising damage to healthy tissue. As a result, TRT offers improved patient outcomes and fewer side effects compared to conventional cancer treatments. In this article, we will discuss the principles of TRT, its advantages, and potential future developments.
Principles of Targeted Radionuclide Therapy
TRT involves using a vector molecule, such as an antibody, peptide, or small molecule, which binds to specific cancer cell receptors or antigens. This vector molecule is conjugated to a radioactive isotope, such as Lutetium-177 (¹⁷⁷Lu), Yttrium-90 (⁹⁰Y), or Radium-223 (²²³Ra), creating a targeted radiopharmaceutical. Once administered, the radiopharmaceutical circulates throughout the body, binding specifically to cancer cells and delivering targeted radiation to the tumour.
The radiation emitted by the radioactive isotope causes localised ionisation events, resulting in DNA damage, generation of reactive oxygen species, and subsequent cell death. Therefore, the choice of the radioactive isotope depends on the specific properties required for effective treatment, such as the type and energy of radiation emitted, half-life, and chemical compatibility with the vector molecule.
Advantages of Targeted Radionuclide Therapy
There are several advantages of TRT over traditional cancer therapies, such as chemotherapy and external beam radiation therapy:
Future Developments and Conclusion
Research into TRT is rapidly expanding, with numerous clinical trials investigating its safety and efficacy in various cancer types. As our understanding of TRT improves, advancements in vector molecule design, isotope production, and dosimetry may further enhance this treatment modality’s therapeutic efficacy and safety profile.
Combining TRT with other cancer treatments, such as immunotherapy, targeted therapies, or chemotherapy, could lead to synergistic effects and improved patient outcomes. Additionally, the development of theranostic approaches, which combine diagnostic imaging and therapy in a single radiopharmaceutical, holds great potential for personalised medicine and treatment monitoring.
You are here:
home »
By | 5 minutes of readingTargeting Neurotensin Receptor-1 with Lutetium-177 IPN-01087 demonstrates promising precision therapy, delivering beta radiation for treating invasive cancers like ductal pancreatic adenocarcinoma.
Targeting Neurotensin Receptor-1: Lutetium-177 IPN-01087 in Oncology Read Post »
By | 4 minutes of readingRevolutionising cancer therapy, Lutetium-177 FAP-2286 offers precise diagnostics and targeted treatment, addressing solid tumours and fibrotic conditions effectively.
By | 9 minutes of readingLutetium-177 Edotreotide revolutionises neuroendocrine tumour treatment through targeted radioligand therapy, enhancing precision and improving patient outcomes.
By | 9 minutes of readingLutetium-177 DOTA-EB-TATE enhances neuroendocrine tumour therapy by improving tumour uptake, retention, and pharmacokinetics through albumin-binding Evans blue moieties.
Neuroendocrine Tumour Therapy: The Rise of Lutetium-177 DOTA-EB-TATE Read Post »
By | 5 minutes of readingmRNA technology revolutionises medicine by enabling rapid, cost-effective treatments, including vaccines, cancer therapies, and solutions for genetic and chronic diseases.
mRNA Technology: A Revolution in Medical Science Read Post »
By | 4 minutes of readingLutetium-177 CTT1403, an innovative PSMA-targeted therapy with irreversible phosphoramidate-based binding, shows remarkable efficacy in treating metastatic prostate cancer, enhancing tumour uptake, internalisation, and therapeutic precision.
Lutetium-177 CTT1403: A Therapeutic Breakthrough in Prostate Cancer Treatment Read Post »
By | 4 minutes of readingExploring Lutetium-177 AMTG highlights its innovative design, enhanced metabolic stability, and potential for effectively treating GRPR-positive prostate and breast tumours.
By | 5 minutes of readingIodine-131 Weimeisheng revolutionises advanced lung cancer treatment by combining targeted monoclonal antibody precision with beta radiation for improved outcomes.
Iodine-131 Weimeisheng: Transforming Advanced Lung Cancer Treatment Read Post »
By | 4 minutes of readingIodine-131 TM601, a synthetic radiolabelled peptide, targets tumour cells expressing Annexin A2, delivering therapeutic radiation and exhibiting anti-angiogenic properties effectively.
Iodine-131 TM601: Targeting Tumours with Radiolabelled Peptides Read Post »
By | 5 minutes of readingPeptide Receptor Radionuclide Therapy utilises radiopharmaceuticals to target somatostatin receptor-expressing tumours, improving treatment outcomes significantly.
By | 5 minutes of readingIodine-131 RPS-001, a radiolabelled small molecule targeting PSMA, shows promise in prostate cancer therapy through precision-directed beta radiation delivery.
Iodine-131 RPS-001: A Promising Radiolabelled Molecule in Prostate Cancer Therapy Read Post »
By | 6 minutes of readingIodine-131 naxitamab (¹³¹I-3F8) targets GD2-expressing cancers, offering precise radioimmunotherapy for neuroblastoma, melanoma, and small cell lung carcinoma.
The Role of Iodine-131 Naxitamab (¹³¹I-3F8) in Treating Neuroblastoma and Other Cancers Read Post »
By | 6 minutes of readingRBE in proton therapy quantifies biological damage relative to conventional radiation, enhancing treatment precision significantly.
RBE and LET: Advancing Precision in Proton Beam Therapy Read Post »
By | 6 minutes of readingFLASH proton therapy utilises ultra-high dose rates to target tumours effectively while sparing surrounding healthy tissues from damage.
Assessing the Feasibility of FLASH Proton Therapy for Patients with Bone Metastases Read Post »
By | 5 minutes of readingBlastoma tumours require advanced imaging techniques like MRI, CT, PET, and ultrasound for accurate diagnosis and staging.
Imaging Techniques Used to Diagnose and Stage Blastoma Tumours Read Post »
By | 6 minutes of readingRadionuclide Therapy Effects include potential organ toxicity, requiring careful monitoring to manage patient outcomes effectively.
Radionuclide Therapy Effects Uncovered: The Hidden Impact on Our Organs Read Post »
By | 6 minutes of readingTritium radiosynthesis enables precise tracking in scientific research, offering critical insights into biochemical pathways and drug development.
Tritium Radiosynthesis: Illuminating the Pathways of Science and Innovation Read Post »
By | 7 minutes of readingCancer radiotheranostics combines targeted radiotherapy and diagnostic imaging to provide personalised, precise, and effective cancer treatment.
Cancer Radiotheranostics: The Future of Targeted Cancer Therapy Read Post »
By | 8 minutes of readingRadiotheranostic treatments combine diagnostic imaging with targeted radiopharmaceutical therapy, providing personalised cancer care with enhanced precision and effectiveness.
Radiotheranostic Treatments: A Guide to Types and Their Clinical Applications Read Post »
By | 13 minutes of readingAlpha particles provide precise cancer treatment by delivering high-energy radiation, targeting tumour cells while sparing healthy tissue.
The Role of Alpha Particles in Radiotheranostics Read Post »
By | 19 minutes of readingThe article explores the theranostic applications of Terbium radionuclides, highlighting their diagnostic and therapeutic potential in nuclear medicine.
Terbium Radionuclides for Theranostic Applications in Nuclear Medicine Read Post »
By | 10 minutes of readingPeptide Receptor Radionuclide Therapy offers a targeted approach to treating neuroendocrine tumours, improving survival rates and quality of life.
Advances in Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumours Read Post »
By | 7 minutes of readingAuger electrons, crucial in surface science and medical physics, enable detailed material characterisation and targeted cancer therapies.
The Fascinating World of Auger Electrons: From Discovery to Modern Applications Read Post »
By | 9 minutes of readingAlpha particles, with high ionising power and low penetration, significantly impact biological tissues when internalised in the body.
Alpha Particles: Their Properties, Sources, Interactions, and Applications Read Post »
By | 5 minutes of readingDosimetry in radionuclide therapy plays a crucial role in optimising treatment effectiveness and ensuring patient safety and well-being.
Precision in Treatment: The Role of Dosimetry in Radionuclide Therapy Read Post »
By | 23 minutes of readingTargeted Alpha Radionuclide Therapy precisely delivers potent alpha particles to tumors, maximising efficacy while sparing healthy tissues.
The Role of Targeted Alpha Radionuclide Therapy in Modern Oncology Read Post »
By | 21 minutes of readingQ&A – Medical Imaging Modalities and Therapy explores innovative techniques and advancements in diagnostic and therapeutic imaging applications.
By | 3 minutes of readingIodine-131 IMAZA innovatively binds to adrenal cortex enzymes, revolutionizing the treatment and imaging of adrenocortical carcinoma effectively.
By | 3 minutes of readingIodine-131 ICF01012, targeting melanin receptors, shows promise in the fight against metastasised melanomas, heralding a new era in treatment.
By | 3 minutes of readingIodine-131 chTNT, aiming to revolutionise oncology, shows promise in targeting and eradicating tumour cells with precision.
Exploring Iodine-131 chTNT: A Beacon of Hope in Cancer Treatment Read Post »
By | 3 minutes of readingIodine-131 CAM-H2 heralds a new era in oncology, offering hope through precise targeting of HER2-expressing cancers with minimal side effects.
Exploring Iodine-131 CAM-H2 for Treating HER2-Expressing Cancers Read Post »
By | 3 minutes of readingIodine-131 BA52, a melanin-binding therapeutic, offers new hope for patients with melanin-positive malignant melanomas.
Exploring Iodine-131 BA52: A Novel Melanin-Targeted Therapy for Malignant Melanomas Read Post »
By | 3 minutes of readingTargeting Blood Cancers: The Role of Iodine-131 Apamistamab in Revolutionising Treatment for AML and Beyond.
The Role of Iodine-131 Apamistamab for Acute Myeloid Leukaemia Read Post »
By | 3 minutes of readingWorld Theranostics Day honours Dr. Hertz’s groundbreaking radioiodine therapy, transforming disease treatment globally since 1941.
Celebrating World Theranostics Day Honoring Saul Hertz Read Post »
By | 3 minutes of readingIodine-131 Monoclonal Antibody 81C6 specifically targets glioma cells by honing in on the tenascin protein.
Iodine-131 Monoclonal Antibody 81C6 Targets Glioma Cells Read Post »
By | 3 minutes of readingHolmium-166 Phytate, initially developed for chronic synovitis, has shown significant promise in phase I/II clinical trials.
Holmium-166 Phytate Offers a Promising Treatment Option for Chronic Synovitis Read Post »
By | 3 minutes of readingHolmium-166 Chitosan, a groundbreaking radiopharmaceutical, offers new hope in treating hepatocellular carcinoma with targeted therapy.
Holmium-166 Chitosan in Radiopharmaceutical Cancer Treatment Read Post »
By | 3 minutes of readingCopper-67 SARTATE emerges as a groundbreaking radiopharmaceutical in targeted cancer therapy, showcasing promising clinical trial results.
Unlocking the Potential of Copper-67 SARTATE in Targeted Radiopharmaceutical Therapy Read Post »
By | 3 minutes of readingCopper-67 SARbisPSMA offers new hope in targeting and treating prostate cancer with precision and effectiveness.
Copper-67 SARbisPSMA New Frontier in Prostate Cancer Treatment Read Post »
By | 3 minutes of readingCopper-64 Diasparagine offers a promising breakthrough in targeting and treating aggressive brain tumours like glioblastoma.
By | 3 minutes of reading213Bi-Lintuzumab demonstrated efficacy in AML treatment, offering a targeted approach with manageable side effects, yet development paused.
Bismuth-213 Lintuzumab: A Promising Treatment for Acute Myeloid Leukaemia Read Post »
By | 3 minutes of reading211At-Parthanatine, targeting PARP1 with alpha radiation, promises precise cancer therapy, especially for high-risk neuroblastomas.
By | 3 minutes of reading211At-MX35-F(ab’)2 shows promise in treating ovarian cancer through targeted therapy in ongoing clinical trials.
The Potential of Astatine-211-MX35-F(ab’)2 in Ovarian Cancer Treatment Read Post »
By | 15 minutes of readingTheragnomics melds theranostics and radiomics, promising targeted cancer therapies with improved outcomes through precision diagnostics and treatment adaptation.
Combining Theranostics and Radiomics: The Emergence of Theragnomics Read Post »
By | 17 minutes of readingTherapeutic nuclear medicine leverages radionuclides for targeted cancer treatment, facing challenges in delivery, safety, and regulatory compliance.
By | 2 minutes of readingNeuroblastoma Targeting Agents offer innovative diagnostic and therapeutic options, revolutionizing treatment with precise targeting and efficacy.
Neuroblastoma Targeting Agents: An Insight into Diagnostic and Therapeutic Advances Read Post »
By | 2 minutes of readingTechnetium-99m and Radium-223 are pivotal in managing bone metastases, enhancing both diagnostic accuracy and therapeutic efficacy.
By | 3 minutes of reading211At-BC8-B10, targeting CD45 in leukemia, combines BC8 antibody with Astatine-211, showing promising clinical trials.
Astatine-211 BC8-B10: A Promising Radioimmunoconjugate for Leukaemia Treatment Read Post »
By | 3 minutes of readingAstatine-211 in radiotheranostics offers targeted, effective cancer treatment, but faces production and safety challenges.
Astatine-211 Radiotheranostics: A New Era in Cancer Treatment Read Post »
By | 4 minutes of reading225Ac-PSMA-617 revolutionises prostate cancer treatment, offering targeted, effective therapy with promising clinical trial results.
Actinium-225 PSMA-617: Revolutionising Prostate Cancer Treatment Read Post »
By | 3 minutes of reading225Ac-Lintuzumab, targeting CD33, shows promise in AML treatment with potential expansion to other cancers.
Actinium-225 Lintuzumab: A Breakthrough in Acute Myeloid Leukaemia Treatment Read Post »
By | 3 minutes of readingActinium-225 is a rare, promising isotope revolutionizing targeted alpha therapy for various resistant cancers.
Actinium-225: The Emerging Star in Targeted Alpha Therapy Read Post »
By | 4 minutes of reading225Ac-FPI-2068 and 111In-FPI-2107 represent a major advancement in targeted alpha therapy for various solid tumours.
By | 3 minutes of readingLutetium-177 Dotatate selectively binds to SSTRs on NET cells, delivering targeted radiation, minimizing collateral damage, and reducing side effects.
Lutetium-177 Dotatate: A Novel Therapeutic Approach in Neuroendocrine Tumours Read Post »
By | 2 minutes of readingIndium-111 Pentetate enables tumour detection, infection, inflammation tracking, and cerebrospinal fluid leak identification.
Indium-111 Pentetate: Targeted Therapy in Oncology, Infection, and Inflammation Read Post »
By | 13 minutes of readingTopics on PET imaging, automated radiosynthesis, breast cancer, prostate cancer therapy and ultrasound.
Inaugural editorial review: nuclear medicine, diagnostic imaging and therapy Read Post »
